Methylprednisolone — Drug Intelligence | 62 EU Trials

Filter these 62 trials by condition, phase, country and more.

Open in Search →

62 Registered trials

28 Recruiting

26 Completed trials

38 Sponsors

27 Countries

Phase III

Phase II

Phase III: 32 Phase II: 20 Phase I/II: 4 Phase IV: 4 Phase I: 1 Phase I (FiH): 1

Oversight events:

2 serious breaches 40 temporary halts 6 urgent safety measures 4 unexpected events 3 corrective measures across 16 trials

View oversight register →

Indications tested

Multiple sclerosis 5 Relapsing multiple sclerosis 3 Relapsing-remitting multiple sclerosis 3 Chronic graft versus host disease 2 Polymyositis 2 Multiple sclerosis relapse 2 Dermatomyositis 2 Follicular lymphoma 1 Injection site pain 1 Meniere's disease 1 Myelin oligodendrocyte glycoprotein antibody-associated disease 1 Primary myelofibrosis 1

Sponsors using this IMP

Assistance Publique Hopitaux De Paris 7 F. Hoffmann-La Roche AG 6 Kite Pharma Inc. 6 Charite Universitaetsmedizin Berlin KöR 2 Hansa Biopharma AB 2 Incyte Corp. 2 Pfizer Inc. 2 Prevail Therapeutics Inc. 2 Rigshospitalet 2 Tg Therapeutics Inc. 2 Tiohundra AB 2 Argenx 1

All trials — page 3

62 total

Phase 2a, double-blind, randomized, placebo-controlled trial of methylprednisolone versus placebo in patients with cognitive deficits in pos… Ended

2023-504826-21-00 Phase II 1 country Charite Universitaetsmedizin Berlin KöR
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab … Ended

2023-506250-20-00 Phase III 8 countries InflaRx GmbH
A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE) Ended

2022-502227-22-00 Phase II 7 countries Kezar Life Sciences Inc.
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult… Ended

2022-502552-31-00 Phase II 7 countries Biogen Idec Research Limited
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended

2022-500121-33-01 Phase III 12 countries Hansa Biopharma AB
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501259-10-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501260-18-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancie… Ended

2022-501261-46-00 Phase II 7 countries Kite Pharma Inc.
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell … Ended

2022-501262-21-00 Phase II 7 countries Kite Pharma Inc.
Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrom… Ended

2024-515857-93-00 Phase II 1 country Istituto Di Ricerche Farmacologiche Mario Negri
EFRAIM II _ Empirical steroids and/or antifungals treatment of immunocompromised patients with acute respiratory failure of uknown origin: a… Ended

2024-514344-82-00 Phase III 1 country Assistance Publique Hopitaux De Paris
A Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients with Multiple Sclerosis Previously Enrolled in A F. Hoffmann-la … Ended

2023-506543-41-00 Phase III 14 countries F. Hoffmann-La Roche AG
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2) Ended

2023-506641-35-00 Phase II 4 countries Kite Pharma Inc.
VAsopressin and STeroids in addition to Adrenaline in cardiac arrest - a randomized clinical trial. VAST-A Expired

2022-500137-89-00 Phase III 1 country Tiohundra AB

Showing 49–62 of 62 trials

← All drugs A–Z